UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 1823, 2026

ImmunityBio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-37507

43-1979754

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3530 John Hopkins Court

San Diego, California 92121

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (844) 696-5235

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

IBRX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to ~~Section 13~~Section13(a) of the Exchange Act. ☐

~~Item~~Section ~~8.01 Other~~2 ~~Events.~~– Financial Information

OnItem ~~February 18, 2026, ImmunityBio, Inc~~2.02 Results (“ImmunityBio” or the “Company”) issued a press release announcing that the Company has received authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, which expands global access of ~~our~~Operations ~~product~~and toFinancial ~~33 countries~~Condition.

AOn ~~copy~~February of23, 2026, ImmunityBio, Inc. (the Company) issued a press release isproviding ~~attached~~a ~~hereto~~business update and announcing its financial results for the fourth quarter and year ended December 31, 2025, and its financial position as ~~Exhibit~~of December 9931, 2025.1 toThe ~~this~~full ~~Current~~text ~~Report~~of onthe ~~Form 8-K~~Company’s ~~and~~press release is furnished as Exhibit 99.1 hereto.

The information infurnished ~~this~~pursuant to Item 82.~~01,~~02 of this Current Report on Form 8-K (including Exhibit 99.1) ~~attached hereto,~~ shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall itsuch information be deemed incorporated by reference ininto any ~~filing~~filings of the Company made under the ~~Securities~~Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Section 9 – Financial Statements and Exhibits.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit Number						Description of Exhibit
99.1**						Press release dated February 1823, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

_______________

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		IMMUNITYBIO, INC.
		Registrant
Date: February 18, 2026	By:	/s/ David C. Sachs
Date: February 23, 2026	By:	/s/ David C. Sachs
		David C. Sachs
		Chief Financial Officer

Filing Compare · ImmunityBio, Inc.